Sumanta K. Pal: PIVOT09 comparing pegylated IL2/nivolumab to TKI by Nizar Tannir et al.
Sumanta K. Pal shared a post on X:
“Huge congrats to Nizar Tannir, MD Anderson Cancer Center, who drove forward this impt trial (PIVOT09) comparing pegylated IL2/nivolumab to TKI; was a privelege to work w him & others (Maria Nirvana Formiga, Neeraj Agarwal, Dan George) on this trial now in Journal of Clinical Oncology. PFS & OS no different; RR a bit lower in experimental arm. We saw Brian Rini & Toni Choueiri present genomic data from KN426 & CLEAR at ASCO24 & prev saw genomic data from CM214 presented by Robert Motzer. Wish we had the opportunity to look at that here – given modest activity w bempeg, could offer insights on which pts could get IO monotx – something we discuss often after KN427 but do infrequently in practice.”
Source: Sumanta K. Pal/X
Sumanta (Monty) Pal, MD, is a medical oncologist and an expert in genitourinary cancers at the City of Hope Comprehensive Cancer Center in Los Angeles. He serves as the co-director of the Kidney Cancer Program and leads the Kidney and Bladder Cancer Disease Team at City of Hope. He specialises in kidney, bladder, and prostate cancers.
